NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - Update
EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on Today's Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements in epilepsy treatment and NeuroOne's breakthrough OneRF® Ablation System.
The full interview can be viewed online here.
Over 50 million people worldwide are affected by epilepsy, with nearly one-third of patients experiencing seizures that do not respond to medication. For these individuals, alternative treatment options, including Radiofrequency (RF) ablation therapy, offer a promising solution.
NeuroOne's OneRF® ablation system, is the first and only FDA 510(k)-cleared device capable of both recording brain activity and performing an RF ablation using the same device. The system has three main components: an electrode that stimulates, records and monitors brain activity with the capability to also perform an ablation, a temperature probe, and a radio frequency heat generator system.
"It was my pleasure to take part in this engaging conversation with Elizabeth Hart and Dr. Clark about the latest treatment options for epilepsy. The OneRF® system represents a significant advancement, offering a more efficient and precise approach for patients who still experience seizure activity after using traditional medication options," said Dave Rosa, CEO of NeuroOne. "By combining real-time monitoring with targeted ablation in a single procedure, we are not only improving patient outcomes but also reducing the need for multiple invasive surgeries."
To learn more about NeuroOne and its groundbreaking work in epilepsy treatment, as well as the potential for our OneRF® platform to be used in pain management, please visit nmtc1.com.
About NeuroOne
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne's current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "forecasts," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential for our OneRF® platform to be used in pain management our business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
Caution: Federal law restricts this device to sale by or on the order of a physician.
IR Contact
Chris Donovan
MZ Group – MZ North America
(914) 352-5853
[email protected]
